Soufflé Therapeutics develops a proprietary platform that discovers cell‑type‑specific receptors, engineers high‑affinity ligands, and designs potent siRNA molecules to deliver gene‑silencing therapies directly into targeted tissues such as skeletal muscle and heart. By enabling precise, safe, and durable intracellular delivery of siRNA, the company creates medicines for rare genetic disorders and broader indications, and partners with pharma and biotech firms to advance these therapies toward clinical trials.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
6OFounders
Product
Problem
Delivering nucleic acid therapeutics such as siRNA to specific cell types throughout the body is technically challenging, limiting the ability to treat diseases that arise from gene expression in tissues beyond the liver. Existing delivery systems often lack the precision, safety, or durability needed for rare genetic disorders and broader indications.
Solution
Soufflé Therapeutics has built a proprietary platform that combines cell‑specific receptor discovery, ligand optimization, and advanced siRNA engineering to create delivery vectors that internalize into targeted cells. By engineering ligands that bind uniquely to receptors on skeletal muscle, cardiomyocytes, and other tissues, the platform enables precise intracellular delivery of siRNA medicines. The approach is designed to produce stronger, safer, and longer‑lasting gene‑silencing effects across multiple cell types. Soufflé is advancing pre‑clinical programs and plans clinical trials for therapies addressing Facioscapulohumeral Muscular Dystrophy and phospholamban‑related cardiomyopathies, with the platform intended to support additional rare and common indications.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing nucleic‑acid‑based therapeutics, as well as patients with rare genetic muscle and cardiac disorders that require targeted gene‑silencing treatments.
Features
- Proprietary pipeline for identifying cell‑type‑specific surface receptors
- Optimized ligand engineering that mediates high‑affinity binding and efficient internalization
- Potent siRNA design framework to achieve durable gene knockdown with minimal off‑target activity
- Modular delivery system applicable to diverse tissues such as skeletal muscle and heart muscle
- Integrated pre‑clinical development workflow that accelerates candidate selection and safety assessment